Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals

On Aug. 19 2013, Johnson & Johnson completed its acquisition of Aragon Pharmaceuticals, a pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. Development of compounds from Aragon’s androgen receptor antagonist program, including its androgen receptor signaling inhibitor, ARN-509, will be managed by Janssen Research & Development.

Source: Johnson & Johnson